Bob Gaskill

I have been in medical device my entire career, with a focus on implantable cardiac devices. I have also focused on what brings value to customers and patients, which inturn improves company value.

Over 35 years in medical device product development at Guidant/Boston Scientific and Medtronic. Spanned numerous technologies, functions, and therapies. Led and was a member of teams that developed valuable technical improvements in implantable defibrillators, pacemakers, and patient management systems. Bob is an accomplished medical device senior leader with a history of success in delivering value in product innovation. He has deep experience in engineering leadership, product development, program management, strategic planning, team development, and managing complexity. BSEE from the University of Iowa. MBA from the University of St. Thomas.

North American EP Technology has exciting and much-needed innovation for the implantable cardioverter defibrillator (ICD) market that addresses critical unmet needs and drives clinical value.

There is substantial clinical evidence that ICDs save lives. Numerous clinical trials have demonstrated this. Two critical unmet needs remain:

1. Lead complications – improvements have been made, but there is still room to improve. Get the leads out of the heart while maintaining antitachycardia pacing (ATP) expectations of transvenous ICDs.
2. Inappropriate shocks—this continues to be a challenge. Clinical studies indicate that reducing inappropriate shocks improves all-cause mortality by 45-55%. ~40 to 60% of the shocks delivered are considered inappropriate.
   We have comprehensive and innovative solutions for both. Solving these unmet needs will significantly improve patient outcomes, reduce therapy costs, and increase patient access.
   
   Two successful preclinical studies confirm our updated sensing technology and achieve low-pacing thresholds to support ATP. Our system requires surgical updates to the ICD hardware and firmware while leveraging the main design.
   
   The global ICD market is estimated to be ~ $5 billion. The North American EP Technology product will participate in all aspects of the ICD market. We believe that we will create markets and take market share by reducing lead complications and inappropriate shocks—both of which inhibit penetration of this life-saving therapy.
   
   Our founder and CEO is Yanhui Li, MD, PhD, a seasoned electrophysiologist and teaching professor with over thirty years of experience in China and the US. Our CTO, Bob Gaskill, is a medical device industry veteran with over 35 years of experience at CPI/Guidant/Boston Scientific and Medtronic. Their expertise and leadership are instrumental in driving our innovation and success.
   
   Our board and advisors include Milton Morris, PhD, Paul McLean, and Bruce KenKnight, PhD. These three have deep ICD experience in business development, sales leadership, research, and finance, in addition to further expertise in startups with successful exits. Their engagement further validates our technology and innovation.